Sign in with Google
bullish
Imugene (IMU AU): Promising Pipeline And Financial Muscle Power Are Biggest Strengths
340 Views24 May 2022 06:18
SUMMARY
- Imugene Ltd (IMU AU) shares faced panic-selling after the announcement of termination of the company’s supply contract with Merck. However, the study will continue with alternative supply arrangement.
- Recently, Imugene published a letter to the shareholders describing the strength and near-term catalyst of the company, which provided some respite to the stock.
- Overall, Imugene, with a cash balance of A$109 million, is well-funded to advance its unique immune-oncology pipeline toward commercial success.
Related Insights
More »Loading
Trending Collections
More »Trending Insights
More »- HEW: Doves Disappointed By Patience
- East Buy Holdings (1797 HK): Potential KWEB Deletion in June
- NIFTY INDEX Outlook: Back in an Uptrend - Where To Buy This Dip
- [Japan Activism] ISS Comes Out Supporting Orbis Against Tsuruha/Welcia Merger Ratio
- Korea Small Cap Gem #33: Shinyoung Wacoal [Real Estate Value Is More Than 5x Market Cap]
Top Unpaywalled Insights
More »- The Polycrisis Era (2025–2028): Navigating a World of Overlapping Disruptions
- Our AI-Powered Accounting Risk Trading Strategy Beat the S&P 500 by 2.5x
- India-UK Free Trade Agreement: A New Era for India's Textile Industry
- The Rise of Quant Investing in Crypto w/ Truvius CEO Connor Farley | The New Barbarians #007
- New Research: Unlocking Quantitative Alpha in Cryptocurrency Markets
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Imugene (IMU AU): Got US Patent for Oncolytic Virotherapy- A Crucial Step Forward for US Entry19 Jul 2023
- Imugene (IMU AU) Placement: Extended Runway for Clinical Programs Pipeline at Modest Equity Dilution18 Sep 2022
- Imugene (IMU AU): Clinical Trial Continued to Advance; Cash Position Still Strong25 Aug 2022
- Imugene (IMU AU): Research Partnerships and Fund-Raising Entail Conviction on Solid Tumors Pipeline11 Feb 2022
x